Top

Published in:

01-11-2021 | Radiotherapy | Endocrine Tumors

Multimodality Treatment Improves Locoregional Control, Progression-Free and Overall Survival in Patients with Anaplastic Thyroid Cancer: A Retrospective Cohort Study Comparing Oncological Outcomes and Morbidity between Multimodality Treatment and Limited Treatment

Authors: Pascal K. C. Jonker, MD, John Turchini, BMedSc, MBBS, FRCPA, Schelto Kruijff, MD, PhD, Jia Feng Lin, BSc, Anthony J. Gill, MD, FRCPA, Thomas Eade, MD, Ahmad Aniss, MSc, PhD, Roderick Clifton-Bligh, MD, PhD, Diana Learoyd, MBBS, FRACP, PhD, Bruce Robinson, MD, MSc, FRACP, Venessa Tsang, MBBS, BSc(Med), FRACP, PhD, Anthony Glover, MBBS, FRACS, PhD, Stanley Sidhu, MD, FRACS, PhD, Mark Sywak, MBBS, FRACS, MMed Sci

Published in: Annals of Surgical Oncology | Issue 12/2021

Abstract

Background

Patients with anaplastic thyroid cancer (ATC) have poor overall survival, and the optimal management approach remains unclear. The aim of this study is to evaluate our experience with multimodality (MMT) versus limited treatment (LT) for ATC.

Patients and Methods

A cohort study of patients with ATC managed in a tertiary referral center was undertaken. The outcomes of MMT were compared with those of LT. The primary outcome measures were locoregional control and progression-free and overall survival. Secondary outcome measures were treatment-related complications and factors associated with improved survival.

Results

In total, 59 patients (35 females) with a median age of 73 years (range 39–99 years) and ATC stage IVA (n = 2), IVB (n = 28), or IVC (n = 29) were included. LT was utilized in 25 patients (42%), and 34 cases had MMT. MMT patients had a longer time of locoregional control (18.5 versus 1.9 months; p < 0.001), progression-free survival (3.5 versus 1.2 months; p < 0.001), and overall survival (6.9 versus 2.0 months; p < 0.001) when compared with LT. For patients with stage IVC ATC, locoregional control (p = 0.03), progression-free survival (p < 0.001), and overall survival (p < 0.001) were superior in the MMT cohort compared with LT. MMT had more treatment-related complications than LT (p < 0.001). An Eastern Cooperative Oncology Group performance status < 2 (HR 0.30; p = 0.001) and MMT (HR 0.35; p = 0.008) were associated with improved overall survival.

Conclusion

MMT is likely to improve locoregional control, progression-free survival, and overall survival in selected ATC patients including stage IVC tumors but comes with a greater complication risk.

Available only for authorised users

Molinaro E, Romei C, Biagini A, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nature Publishing Group. 2017. https://doi.org/10.1038/nrendo.2017.76.CrossRef

Glaser SM, Mandish SF, Gill BS, Balasubramani GK, Clump DA, Beriwal S. Anaplastic thyroid cancer: prognostic factors, patterns of care, and overall survival. Head Neck. 2016;38(S1):E2083–90. https://doi.org/10.1002/hed.24384.CrossRefPubMed

Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012;22(11):1104–39. https://doi.org/10.1089/thy.2012.0302.CrossRefPubMed

Corrigan KL, Williamson H, Elliott Range D, Niedzwiecki D, Brizel DM, Mowery YM. Treatment outcomes in anaplastic thyroid cancer. J Thyroid Res. 2019;2019:8218949–9011. https://doi.org/10.1155/2019/8218949.CrossRefPubMedPubMedCentral

Prasongsook N, Kumar A, Chintakuntlawar AV, et al. Survival in response to multimodal therapy in anaplastic thyroid cancer. J Clin Endocrinol Metab. 2017;102(12):4506–14. https://doi.org/10.1210/jc.2017-01180.CrossRefPubMed

Lee DY, Won J-K, Choi HS, et al. Recurrence and survival after gross total removal of resectable undifferentiated or poorly differentiated thyroid carcinoma. Thyroid. 2016;26(9):1259–68. https://doi.org/10.1089/thy.2016.0147.CrossRefPubMed

Mohebati A, DiLorenzo M, Palmer F, et al. Anaplastic thyroid carcinoma: a 25-year single-institution experience. Ann Surg Oncol. 2014;21(5):1665–70. https://doi.org/10.1245/s10434-014-3545-5.CrossRefPubMed

Brignardello E, Palestini N, Felicetti F, et al. Early surgery and survival of patients with anaplastic thyroid carcinoma: analysis of a case series referred to a single institution between 1999 and 2012. Thyroid. 2014;24(11):1600–6. https://doi.org/10.1089/thy.2014.0004.CrossRefPubMed

Sugitani I, Miyauchi A, Sugino K, Okamoto T, Yoshida A, Suzuki S. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan Cohort Study of 677 patients. World J Surg. 2012;36(6):1247–54.CrossRef

10.

Ito K-I, Hanamura T, Murayama K, et al. Multimodality therapeutic outcomes In anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors. Head Neck. 2011;34(2):230–7. https://doi.org/10.1002/hed.21721.CrossRefPubMed

11.

Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid. 2011;21(1):25–30. https://doi.org/10.1089/thy.2010.0220.CrossRefPubMed

12.

Sherman EJ, Lim SH, Ho AL, et al. Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review. Radiother Oncol. 2011;101(3):425–30. https://doi.org/10.1016/j.radonc.2011.09.004.CrossRefPubMed

13.

Troch M, Koperek O, Scheuba C, et al. high efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J Clin Endocrinol Metab. 2010;95(9):E54–7. https://doi.org/10.1210/jc.2009-2827.CrossRefPubMed

14.

Swaak-Kragten AT, de Wilt JHW, Schmitz PIM, Bontenbal M, Levendag PC. Multimodality treatment for anaplastic thyroid carcinoma—treatment outcome in 75 patients. Radiother Oncol. 2009;92(1):100–4. https://doi.org/10.1016/j.radonc.2009.02.016.CrossRefPubMed

15.

Goutsouliak V, Hay JH. Anaplastic thyroid cancer in British Columbia 1985–1999: a population-based study. Clin Oncol. 2005;17(2):75–8. https://doi.org/10.1016/j.clon.2004.07.013.CrossRef

16.

Tennvall J, Lundell G, Wahlberg P, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer. 2002;86(12):1848–53. https://doi.org/10.1038/sj.bjc.6600361.CrossRefPubMedPubMedCentral

17.

De Crevoisier R, Baudin E, Bachelot A, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60(4):1137–43. https://doi.org/10.1016/j.ijrobp.2004.05.032.CrossRefPubMed

18.

Machens A, Hinze R, Lautenschläger C, Thomusch O, Dunst J, Dralle H. Extended surgery and early postoperative radiotherapy for undifferentiated thyroid carcinoma. Thyroid. 2001;11(4):373–80. https://doi.org/10.1089/10507250152039127.CrossRefPubMed

19.

Haigh PI, Ituarte PH, Wu HS, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer. 2001;91(12):2335-2342. http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=11413523&retmode=ref&cmd=prlinks.

20.

Pierie J-PEN, Muzikansky A, Gaz RD, Faquin WC, Ott MJ. The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol. 2002;9(1):57–64. https://doi.org/10.1245/aso.2002.9.1.57.CrossRefPubMed

21.

Nachalon Y, Stern-Shavit S, Bachar G, Shvero J, Limon D, Popovtzer A. Aggressive palliation and survival in anaplastic thyroid carcinoma. JAMA Otolaryngol Head Neck Surg. 2015;141(12):1128–35. https://doi.org/10.1001/jamaoto.2015.2332.CrossRefPubMed

22.

Maniakas A, Dadu R, Busaidy NL, et al. Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000–2019. JAMA Oncol. 2020;6(9):1397–8. https://doi.org/10.1001/jamaoncol.2020.3362.CrossRefPubMed

23.

Fan D, Ma J, Bell AC, et al. Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer. Cancer. 2019;126(2):444–52. https://doi.org/10.1002/cncr.32548.CrossRefPubMed

24.

Baek S-K, Lee M-C, Hah JH, et al. Role of surgery in the management of anaplastic thyroid carcinoma: Korean nationwide multicenter study of 329 patients with anaplastic thyroid carcinoma, 2000 to 2012. Head Neck. 2016;39(1):133–9. https://doi.org/10.1002/hed.24559.CrossRefPubMed

25.

Haymart MR, Banerjee M, Yin H, Worden F, Griggs JJ. Marginal treatment benefit in anaplastic thyroid cancer. Cancer. 2013;119(17):3133–9. https://doi.org/10.1002/cncr.28187.CrossRefPubMed

26.

Lloyd RV, Osamura RY, Klöppel G, Rosai J, World Health Organization., International Agency for Research on Cancer. WHO Classification of Tumours of Endocrine Organs. 2017.

27.

Wagle N, Grabiner BC, Van Allen EM, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014;371(15):1426–33. https://doi.org/10.1056/NEJMoa1403352.CrossRefPubMedPubMedCentral

28.

Rosove MH, Peddi PF, Glaspy JA. BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med. 2013;368(7):684–5. https://doi.org/10.1056/NEJMc1215697.CrossRefPubMed

29.

Iwasaki H, Yamazaki H, Takasaki H, et al. Lenvatinib as a novel treatment for anaplastic thyroid cancer: a retrospective study. Oncol Lett. 2018. https://doi.org/10.3892/ol.2018.9553.CrossRefPubMedPubMedCentral

30.

Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7–13. https://doi.org/10.1200/JCO.2017.73.6785.CrossRefPubMed

31.

Harris EJ, Hanna GJ, Chau N, et al. Everolimus in anaplastic thyroid cancer: a case series. Front Oncol. 2019;9:542358–66. https://doi.org/10.3389/fonc.2019.00106.CrossRef

32.

Kollipara R, Schneider B, Radovich M, Babu S, Kiel PJ. Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer. Oncologist. 2017. https://doi.org/10.1634/theoncologist.2017-0096.CrossRefPubMedPubMedCentral

33.

Capdevila J, Wirth LJ, Ernst T, et al. PD-1 blockade in anaplastic thyroid carcinoma. JCO. 2020. https://doi.org/10.1200/JCO.19.02727.CrossRef

Title: Multimodality Treatment Improves Locoregional Control, Progression-Free and Overall Survival in Patients with Anaplastic Thyroid Cancer: A Retrospective Cohort Study Comparing Oncological Outcomes and Morbidity between Multimodality Treatment and Limited Treatment
Authors: Pascal K. C. Jonker, MD
John Turchini, BMedSc, MBBS, FRCPA
Schelto Kruijff, MD, PhD
Jia Feng Lin, BSc
Anthony J. Gill, MD, FRCPA
Thomas Eade, MD
Ahmad Aniss, MSc, PhD
Roderick Clifton-Bligh, MD, PhD
Diana Learoyd, MBBS, FRACP, PhD
Bruce Robinson, MD, MSc, FRACP
Venessa Tsang, MBBS, BSc(Med), FRACP, PhD
Anthony Glover, MBBS, FRACS, PhD
Stanley Sidhu, MD, FRACS, PhD
Mark Sywak, MBBS, FRACS, MMed Sci
Publication date: 01-11-2021
Publisher: Springer International Publishing
Keywords: Radiotherapy
Thyroid Cancer
Thyroid Cancer
Thyroid Cancer
Published in: Annals of Surgical Oncology / Issue 12/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-021-10146-3

2024 ASCO Annual Meeting

Springer Medicine

Multimodality Treatment Improves Locoregional Control, Progression-Free and Overall Survival in Patients with Anaplastic Thyroid Cancer: A Retrospective Cohort Study Comparing Oncological Outcomes and Morbidity between Multimodality Treatment and Limited Treatment

Abstract

Background

Patients and Methods

Results

Conclusion

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Patients and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2021

Guide to Enhanced Recovery for Cancer Patients Undergoing Surgery

Mucinous Colorectal Cancer is Associated With Expression of the TIM-3 Immune Checkpoint Independently of Microsatellite Instability (MSI) Status

Diagnostic Immunostaining and Tumor Markers Predict the Prognosis of Esophageal Neuroendocrine Cell Carcinoma Patients

ASO Author Reflections: AFP Levels at the Time of Recurrence Predict Post-recurrence Outcomes Irrespective of Modality Used to Treat Recurrence

The “Real R0”: A Resection Margin Smaller Than 0.1 cm is Associated with a Poor Prognosis After Oncologic Esophagectomy

Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Metaanalysis of Oncological and Operative Outcomes